Ironwood Pharmaceuticals (NASDAQ: IRWD) — Perfil da empresa, notícias e dados financeiros
Ironwood Pharmaceuticals develops innovative medicines, focusing on gastrointestinal and cardiovascular diseases.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ:IRWD) is a dynamic player in the pharmaceutical field, focusing on the discovery, development, and commercialization of innovative medicines designed to address significant unmet needs. With a keen eye on gastrointestinal and cardiovascular diseases among other therapeutic areas, Ironwood is dedicated to pushing the boundaries of science to improve patient outcomes. A core project is the marketing and further development of Linzess®, a treatment for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), reflecting the company's commitment to tackling prevalent yet challenging conditions. Central to its mission, Ironwood aims to leverage its deep expertise in pharmacology and innovative patient-care approaches to expand its portfolio, driving growth and delivering value to patients and shareholders alike.
Resumo
Operações
Produtos e/ou serviços de Ironwood Pharmaceuticals
- Drug Discovery and Development: They identify and develop potential drug candidates through scientific research and preclinical testing, targeting specific therapeutic areas.
- Clinical Trials: Ironwood conducts clinical trials in humans to evaluate the safety and efficacy of their drug candidates in various stages of development.
- Regulatory Affairs: They work with regulatory agencies like the FDA to obtain marketing approval for their drugs, allowing them to be prescribed to patients.
- Partnerships and Collaborations: They collaborate with other pharmaceutical companies to leverage expertise and resources for broader development and commercialization of their drugs or in-license drugs from other companies for further development and potential commercialization.
- Manufacturing and Supply Chain: While not directly involved in large-scale manufacturing, they may partner with other companies to ensure the quality and supply of their drugs if they reach the market.
- Commercialization (limited): In some cases, Ironwood may participate in limited commercialization activities for their approved drugs, such as sales and marketing efforts alongside their partner companies. However, their primary focus remains on drug discovery, development, and obtaining regulatory approvals.
equipe executiva do Ironwood Pharmaceuticals
- Thomas A. McCourtCEO & Director
- Tammi GaskinsSenior Vice President & Chief Commercial Officer.
- Ronald SilverSenior VP, Interim CFO, Corporate Controller & Chief Accounting Officer
- Rosario LobruttoVP & Global Head of Technical Operations
- Chris StammVice President of Investor Relations & Communications
- John MinardoSenior VP, Chief Legal Officer & Secretary
- Jeff RubertiChief Strategy Officer
- Jeffrey SilberChief Medical Officer, Head of Research & Drug Development
Últimas notícias sobre a Ironwood Pharmaceuticals
Principais indicadores financeiros
Resultados divulgados pela Ironwood Pharmaceuticals, em USD.
- Cap. de mercado
- 596,5 mi
- Receita (TTM)
- 389,3 mi
- P/L
- 4.7
- LPA (diluído, TTM)
- 0.8
- Dividend yield
- —
- Margem de lucro
- 33.4%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 296,2 mi | 118,8 mi | 24 mi | |
| 351,4 mi | 93,1 mi | 880 mil | |
| 442,7 mi | -945,4 mi | -1 bi | |
| 410,6 mi | 250,3 mi | 175,1 mi |